Evidence map›Paper›PMID 39131771›Full record

ArticleInternational journal of cardiology. Cardiovascular risk and prevention2024

An interesting case series of ticagrelor induced long QTc.

Alireza Farzaei, Entezar Mehrabi Nasab, Yaser Jenab, Alireza Amirzadegan, Alireza Khodayari Javazm, Mokhtar Eisvand, Fateme Hajzeinolabedini, Ali Bozorgi

Abstract readCase Reports
In one paragraph

Article in International journal of cardiology. Cardiovascular risk and prevention, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alireza FarzaeiTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Science, Tehran, Iran.
Entezar Mehrabi NasabDepartment of Cardiology, School of Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Yaser JenabTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Science, Tehran, Iran.
Alireza AmirzadeganTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Science, Tehran, Iran.
Alireza Khodayari JavazmTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Science, Tehran, Iran.
Mokhtar EisvandTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Science, Tehran, Iran.
Fateme HajzeinolabediniFaculty of Medicine, Kermanshah University of Medical Science, Kermanshah, Iran.
Ali BozorgiDepartment of Cardiology, School of Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case series explores three patients who underwent percutaneous coronary intervention (PCI) and experienced prolonged QT intervals under treatment with Ticagrelor. The first case was a female who presented with chest pain and received a Xience stent. The second case involved a male patient who received two Xience stents. The third case was that of a male patient with LAD stenosis. All three patients received Ticagrelor and exhibited prolonged QTc intervals on their electrocardiograms (ECGs), which was resolved after switching to Clopidogrel. Thus far, the potential impact of Ticagrelor on QT prolongation has not been adequately addressed in the literature. It is hypothesized that Ticagrelor can block adenosine uptake by red blood cells, which may explain QTc prolongation. The results of this case series indicate that Ticagrelor may prolong QTc intervals. Consequently, it is imperative that clinicians are aware of this previously unlisted side effect and that patients are closely monitored while seeking alternative medications to manage the condition.

Indexed as

ACSLong QTcTicagrelor

Identifiers

PMID39131771
PMCPMC11315159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.